Page 5 - Nsclc News Today

1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed a significant survival benefit with SBRT in comparison to patients with breast cancer. Evidence Rating Level: 1 (Excellent) Study Rundown: Most patients with metastatic breast cancer develop resistance to systemic therapy. Stereotactic body radiotherapy (SBRT)

Joshua K. Sabari, MD, discusses updates in ADCs in NSCLC.

Coverage of Tennessee Oncology's Johann Brandes, MD, on "Precision Medicine in NSCLC."

Joshua K. Sabari, MD, explains the utility of ADCs in patients with NSCLC and their benefit in patients with EGFR-, ALK-, or HER2-mutant disease.

Repotrectinib is under priority review for patients with NTRK-positive locally advanced or metastatic solid tumors and high unmet medical need.

Consolidation durvalumab led to comparable outcomes among older patients with unresectable stage III non–small cell lung cancer (NSCLC) vs a younger cohort with the same cancer; this patient population was underrepresented in the PACIFIC trial.

Joshua K. Sabari, MD, discusses the investigation of patritumab deruxtecan in EGFR-mutant non–small cell lung cancer.

Dr. Gadgeel reviews the HERTHENA-Lung01 trial results of the HER3 targeting antibody drug conjugate patritumab deruxtecan in EGFR-positive non-small cell lung cancer.

The EMA is evaluating a Type II extension of indication application for the approval of first-line amivantamab plus lazertinib in EGFR-mutated NSCLC.

A retrospective study showed consolidated osimertinib after chemoradiation prolonged progression-free survival in patients with EGFR-mutated, stage III NSCLC compared with durvalumab or observation.